Abstract
Background: Erectile dysfunction (ED) affects 30 million men in the US with a decrease in quality of life. Thirty percent of hypertensive men suffer from ED.
Objective: This review will debate the interplay between hypertension and ED, discovering novel insights concerning hypertension-linked ED, as well as the influence of antihypertensive medications on patients with ED.
Method: Total number of records screened from PubMed yielded by the search which performed from January 2000 - June 2018.
Results: Hypertension can cause ED as a consequence of high blood pressure or antihypertensive treatment. Both hypertension and ED have endothelial dysfunction as a common base mechanism, which can lead to an increase in vascular smooth muscle contraction. Also, some phosphodiesterase (PDE)-5 inhibitors used to treat ED can recover blood pressure.
Conclusion: Understanding of common mechanisms involved in ED accompanied with hypertension and the research on antihypertensive drugs that impact ED will bring important approaches for identifying novel therapeutic strategies that will improve quality of life in patients with these conditions.
Keywords: Antihypertensive treatment, endothelial dysfunction, erectile dysfunction, hypertension, phosphodiesterase-5 inhibitors, high blood pressure.
Current Pharmaceutical Design
Title:Management of Erectile Dysfunction: An Under-Recognition of Hypertension
Volume: 24 Issue: 30
Author(s): Gokhan Koroglu, Ecem Kaya-Sezginer, Didem Yilmaz-Oral and Serap Gur*
Affiliation:
- Department of Biochemistry and Pharmacology, Faculty of Pharmacy, Ankara University, Ankara,Turkey
Keywords: Antihypertensive treatment, endothelial dysfunction, erectile dysfunction, hypertension, phosphodiesterase-5 inhibitors, high blood pressure.
Abstract: Background: Erectile dysfunction (ED) affects 30 million men in the US with a decrease in quality of life. Thirty percent of hypertensive men suffer from ED.
Objective: This review will debate the interplay between hypertension and ED, discovering novel insights concerning hypertension-linked ED, as well as the influence of antihypertensive medications on patients with ED.
Method: Total number of records screened from PubMed yielded by the search which performed from January 2000 - June 2018.
Results: Hypertension can cause ED as a consequence of high blood pressure or antihypertensive treatment. Both hypertension and ED have endothelial dysfunction as a common base mechanism, which can lead to an increase in vascular smooth muscle contraction. Also, some phosphodiesterase (PDE)-5 inhibitors used to treat ED can recover blood pressure.
Conclusion: Understanding of common mechanisms involved in ED accompanied with hypertension and the research on antihypertensive drugs that impact ED will bring important approaches for identifying novel therapeutic strategies that will improve quality of life in patients with these conditions.
Export Options
About this article
Cite this article as:
Koroglu Gokhan , Kaya-Sezginer Ecem , Yilmaz-Oral Didem and Gur Serap *, Management of Erectile Dysfunction: An Under-Recognition of Hypertension, Current Pharmaceutical Design 2018; 24 (30) . https://dx.doi.org/10.2174/1381612824666180828104350
DOI https://dx.doi.org/10.2174/1381612824666180828104350 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aldose Reductase, Still a Compelling Target for Diabetic Neuropathy
Current Drug Targets Recent Advances in Transition Metal Free Synthetic Protocols for Quinoline Derivatives
Current Organic Chemistry Editorial [Hot topic: Adenosine Receptor Ligands: Where Are We, and Where Are We Going? (Guest Editors: Tiziano Tuccinardi and Adriano Martinelli)]
Current Topics in Medicinal Chemistry The First Line of Defense Against Cardiac Hypertrophy
Current Molecular Medicine Risk Factors for Myocardial Infarction in Women and Men: A Review of the Current Literature
Current Pharmaceutical Design Heme Oxygenase System and Hypertension: A Comprehensive Insight
Current Pharmaceutical Design Novel Drugs of Abuse: A Snapshot of an Evolving Marketplace
Adolescent Psychiatry Nanosuspension as an Efficient Carrier for Improved Ocular Permeation of Voriconazole
Current Pharmaceutical Biotechnology Individualized Treatment Planning in Oncology: Role of PET and Radiolabelled Anticancer Drugs in Predicting Tumour Resistance
Current Pharmaceutical Design Computational Models and Methods for Drug Target Prediction and Drug Repositioning
Combinatorial Chemistry & High Throughput Screening Elevated Serum Human Cytomegalovirus IgM Levels in the Acute Phase of Ischemic Stroke are Associated with Increased Risk of Death and Major Disability
Current Neurovascular Research Mechanisms, Prevention and Treatment of Distal Embolization
Current Pharmaceutical Design Current Status of Antiplatelet Therapy in Acute Coronary Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Is It Possible to Apply Secondary Stroke Prevention Guidelines to Very Old Populations?
Cardiovascular & Hematological Disorders-Drug Targets Role of ARBs in the Blood Hypertension Therapy and Prevention of Cardiovascular Events
Current Drug Targets 24-Hour Blood Pressure Control – A Predictor for Clinical Outcomes
Current Hypertension Reviews Disease Outcome, Alexithymia and Depression are Differently Associated with Serum IL-18 Levels in Acute Stroke
Current Neurovascular Research Therapeutic Effects of Renal Denervation on Renal Failure
Current Neurovascular Research DL-3-n-Butylphthalide, an Anti-Oxidant Agent, Prevents Neurological Deficits and Cerebral Injury Following Stroke per Functional Analysis, Magnetic Resonance Imaging and Histological Assessment
Current Neurovascular Research Metabolism of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy: A Review of the Literature
Current Drug Metabolism